Pharmaceutical Partners

Strategic Partners

We have strategic partnerships through which we can broadly expand our drug discovery efforts to new disease targets in specific therapeutic areas. Our partners provide expertise, tools and resources to complement our drug discovery efforts. We have established strategic partnerships with the following pharmaceutical industry leaders:

  • Biogen: We have four strategic alliances with Biogen to discover and develop antisense drugs to treat neurologic diseases, including our collaboration to develop and commercialize SPINRAZA, which was approved by the U.S. FDA in December 2016 to treat pediatric and adult patients with SMA (see announcement here). We licensed SPINRAZA to Biogen in 2016 and they are responsible for all global development, regulatory and commercialization activities and costs for SPINRAZA.
  • AstraZeneca: We have two collaboration programs with AstraZeneca, including a broad strategic collaboration to discover and develop antisense drugs to treat cardiovascular and metabolic diseases and a collaboration to discover and develop antisense drugs targeting a small number of specified targets to treat cancer. In 2016, AstraZeneca selected for development IONIS-AZ4-2.5-LRx to inhibit an undisclosed target to treat cardiovascular disease (see announcement here) and licensed IONIS-KRAS-2.5Rx and will advance it in development for the treatment of cancer (see announcement here). We and AstraZeneca are also developing IONIS-STAT3-2.5Rx for the treatment of cancer.

Research, Development and Commercialization Partners

We have partnerships with companies that bring significant expertise and global resources to develop and potentially commercialize drugs for a particular therapeutic area. These partnerships often enable us to accelerate the development of our drugs for broader patient populations where late-stage development would be costly and complex. We have established the following research, development and commercialization partnerships:

  • Bayer: We have an exclusive license agreement with Bayer for the development and commercialization of our Factor XI program. In February 2017, we announced that Bayer will advance IONIS-FXIRx in clinical development and licensed and will initiate development of IONIS-FXI-LRx, which utilizes Ionis’ LICA technology. For additional information about this collaboration, please see our press release here.
  • GSK: We have an alliance with GSK to discover and develop new drugs against targetsfor rare and serious diseases, including infectious diseases and some conditions causing blindness. We are currently conducting a Phase 3 study for IONIS-TTRRx in patients with familial amyloid polyneuropathy (FAP) with data expected in the second quarter of 2017. Our alliance with GSK comprises four drugs: IONIS-TTRRx; IONIS-HBVRx and IONIS-HBV-LRx, both designed to reduce the production of viral proteins associated with HBV infection; and IONIS-GSK4-LRx, which we designed to treat an ocular disease. For additional information about IONIS-TTRRx, please see our most recent press release here.
  • Janssen: We have a broad alliance with Janssen to discover and develop antisense drugs to treat autoimmune disorders in the GI tract. Under this agreement, Janssen has licensed IONIS-JBI1-2.5Rx and has validated an undisclosed target to treat patients with a gastrointestinal autoimmune disease. For additional information about this collaboration, please see our press release here.
  • Novartis: We and Akcea initiated a collaboration with Novartis in 2017 to develop and co-commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for the treatment of patients at high cardiovascular risk due to inadequately treated lipid disorders. After we and Akcea complete Phase 2 development of each drug, Novartis may exercise its option on a drug by drug basis. At such time, Novartis will pay us and Akcea a $150 million license fee for each drug and will be responsible for further development and worldwide commercialization, including conducting and paying for a Phase 3 cardiovascular outcome study for each drug, in high risk patients. Akcea retains the right to co-commercialize any drug Novartis commercializes under this agreement through its specialized sales force focused on lipid specialists in selected markets. For additional information about this collaboration, please see our press release here.
  • Roche: We have an alliance with Roche to discover and develop antisense drugs to treat Huntington’s disease (HD). We are currently evaluating IONIS-HTTRx in a Phase 1/2 study in patients with early stage HD. For additional information about this collaboration, please see our press release here.